4 Einträge gefunden

1. Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3

   1. Reich, K
   2. Iversen, L
   3. Puig, L
   4. Lambert, J
   5. Mrowietz, U
   6. Kaplan Saday, K
   7. Warren, R B

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials

   1. Reich, K
   2. DeLozier, A M
   3. Nunes, F P
   4. Thyssen, J P
   5. Eichenfield, L F
   6. Wollenberg, A
   7. Ross Terres, J A

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
3. Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance

   1. Reich, K
   2. Gordon, K B
   3. Strober, B
   4. Langley, R G
   5. Miller, M
   6. Yang, Y-W
   7. Shen, Y-K

   2022 - Forschungsinformationssystem des UKE
4. Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials

   1. Gordon, K B
   2. Reich, K
   3. Crowley, J J
   4. Korman, N J
   5. Murphy, F T
   6. Poulin, Y
   7. Spelman, L

   2022 - Forschungsinformationssystem des UKE - frei zugänglich